Pfizer

Pfizer advances development of once-daily weight-loss pill (NYSE:PFE)

Buoyed by encouraging pharmacokinetic data from an ongoing study, Pfizer (NYSE:PFE) has decided to proceed with the development of a once-daily formulation of its oral weight-loss drug, danuglipron. Danuglipron (PF-06882961) is an investigational GLP-1 receptor agonist developed in-house at Pfizer. An ongoing open-label, randomized study is evaluating the pharmacokinetics andContinue Reading

GSK, Pfizer decline as CDC advisors recommend narrower age range for RSV shots (NYSE:GSK)

In: Finance

Hailshadow GSK (NYSE:GSK) and Pfizer (NYSE:PFE) both declined in Wednesday trading after the CDC’s Advisory Committee on Immunization Practices recommended an age range for respiratory syncytial virus (RSV) vaccines that wasn’t as broad as drugmakers would have liked. GSK closed down ~3.6%, while Pfizer lost 2%. The panel voted thatContinue Reading

Pfizer advances development of once-daily weight-loss pill (NYSE:PFE)

Generative AI for agriculture: How Agmatix is improving agriculture with Amazon Bedrock | Amazon Web Services

Generate financial industry-specific insights using generative AI and in-context fine-tuning | Amazon Web Services